Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report

Abstract

Abstract Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patient with rituximab for pemphigus vulgaris.

Keywords

• human antichimeric antibodies
• immunosuppressant
• pemphigus vulgaris
• rituximab
• serum sickness